Prognostic role of tumor subtype and germline BRCA mutation in advanced breast cancer patients treated with palbociclib plus endocrine therapy.
Song Yi ParkKoung Jin SuhDae-Won LeeHan Suk RyuMiso KimSe Hyun KimKyung-Hun LeeTae-Yong KimJee Hyun KimIn Ae ParkSeock-Ah ImPublished in: Breast cancer research and treatment (2022)
The efficacy and toxicity of palbociclib in the real world were comparable to those of clinical trials. In addition, palbociclib with endocrine therapy was an effective treatment option for young patients. Luminal B and germline BRCA mutation were associated with inferior outcome.